Detalhe da pesquisa
1.
Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology.
J Clin Pharm Ther
; 36(2): 152-60, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21366643
2.
Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome.
Br J Haematol
; 143(5): 716-20, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19036015
3.
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
Leukemia
; 20(6): 1061-6, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16642048
4.
The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?
Leukemia
; 21(2): 193-4, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17251899
5.
Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation.
Leukemia
; 21(11): 2376-7, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17554376
6.
Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.
Leukemia
; 19(11): 1991-2, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16151468
7.
Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.
Med Mal Infect
; 41(12): 652-6, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22056376
8.
BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.
Leukemia
; 22(4): 791-9, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18216868
9.
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Leukemia
; 22(12): 2176-83, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18754032
10.
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Leukemia
; 22(6): 1200-6, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18401416
11.
Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy.
Leukemia
; 23(6): 1193-6, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19242496